Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?

Mutlu, HASAN; Salim, Derya; Gunduz, ŞEYDA; Eryilmaz, Melek; Musri, Fatma; COŞKUN, HASAN

doi:10.4103/0973-1482.161933

Docetaxel plus cisplatin plus fluorouracil versus carboplatin plus fluorouracil-cetuximab in first-line setting in patients with recurrent or metastatic head and neck squamous cell cancer who did not previously receive neoadjuvant or adjuvant chemotherapy, which is standard?

Atıf İçin Kopyala

Mutlu H., Salim D. K., Gunduz S., Eryilmaz M. K., Musri F. Y., COŞKUN H. Ş.

JOURNAL OF CANCER RESEARCH AND THERAPEUTICS, cilt.13, sa.3, ss.510-513, 2017 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 13 Sayı: 3
Basım Tarihi: 2017
Doi Numarası: 10.4103/0973-1482.161933
Dergi Adı: JOURNAL OF CANCER RESEARCH AND THERAPEUTICS
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.510-513
Anahtar Kelimeler: Cetuximab, chemotherapy, first-line, head, and neck cancer, survival, INDUCTION CHEMOTHERAPY, 5-FLUOROURACIL, CARCINOMA, PACLITAXEL, CHEMORADIOTHERAPY, TRIAL
Akdeniz Üniversitesi Adresli: Evet

Özet

Background: The prognosis of recurrent or metastatic head and neck squamous cell cancer (HNSCC) is very poor. In the present retrospective study, we compared the impact of docetaxel plus cisplatin plus fluorouracil (TCF), and cisplatin plus fluorouracil plus cetuximab (CF-Ctx) regimens on the prognosis of patients with recurrent or metastatic HNSCC in first-line.